Intro
Checkpoint Therapeutics (CKPT) is a majority-controlled subsidiary of Fortress Biotech (FBIO). The Company is focused on the acquisition, development, and commercialization of novel treatments for patients with solid tumors. Its lead candidates are CK-101, which is in Phase 1/2 clinical trial for the treatment of patients with EGFR+ non-small cell lung cancer (or NSCLC) and CK-301, an anti-PD-L1 antibody which is in an ongoing Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic tumors.
Pipeline
CK-101
CK-101 (formerly known as RX518) is an orally available third-generation